FiercePharma

AbbVie's Skyrizi snatches sales crown from Humira as company lifts full-year profit guidance

It’s a new era for AbbVie. For the first time in years, the company has a new top sales driver as Skyrizi has overtaken Humira in quarterly sales. Humira heir Skyrizi has been slowly creeping up on ...
Seeking Alpha

U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease

NORTH CHICAGO, Ill., June 18, 2024 /PRNewswire/ -- AbbVie (ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI ® (risankizumab-rzaa) for adults with moderately to ...
AOL

AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an ...
Healio

Skyrizi snags FDA approval for moderate to severe UC; first IL-23 approved for UC, CD

Please provide your email address to receive an email when new articles are posted on . The FDA has approved Skyrizi for the treatment of adult patients with moderate to severe ulcerative colitis, ...
The Business Journals

AbbVie looks to Skyrizi, other drugs to replace blockbuster Humira sales

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Sales of Skyrizi and Rinvoq ...
AOL

Skyrizi & hair loss: From side effects to treatment options

Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...
Healio

Patients ‘continue to respond’ to subcutaneous Skyrizi despite failed IV induction in UC

Please provide your email address to receive an email when new articles are posted on . Maintenance subcutaneous risankizumab may induce remission in patients with ulcerative colitis who failed IV ...
St. Louis American

U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie’s Portfolio Across Inflammatory Bowel Disease

NORTH CHICAGO, Ill., June 18, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI ® (risankizumab-rzaa) for adults with moderately ...
Nasdaq

Have Skyrizi and Rinvoq Successfully Saved AbbVie From Humira LoE?

AbbVie ABBV expects to return to robust revenue growth in 2025, just two years after losing U.S. exclusivity for its flagship drug, Humira. The drug, which went off-patent in January 2023, saw ...